Search Results

Deals

Endocyte Stockholders Approve Merger Agreement with Novartis AG

Endocyte, Inc. today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.

December 21, 2018

·

3 min read

Press Releases

Judo Bio Presents Data Demonstrating Mechanism of Receptor-mediated Delivery of Oligonucleotides Resulting in Gene Silencing in the Kidney

October 28, 2024

·

3 min read

Business

Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory AffairsBrings 30 Years of Experience as a Former Endocyte and Novartis Regulatory Executive

Chimerix today appointed Christopher L. Jordan as Vice President, Regulatory Affairs.

August 8, 2022

·

3 min read

Press Releases

Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director

November 20, 2024

·

2 min read

Deals

Novartis Plunks Down $2.1 Billion for Endocyte

Shares of Indiana-based Endocyte have shot up more than 50 percent in pre-market trading after Swiss pharma giant Novartis announced it was acquiring the company for $2.1 billion in cash. The deal will allow the company to expand its radiopharmaceuticals business.

October 18, 2018

·

2 min read

·

Alex Keown

Policy

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Endocyte, Inc. In The U.S. District Court For The Southern District Of New York

Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:18-cv-10392-JMF, on behalf of public common shareholders of Endocyte, Inc who held Endocyte securities on the record date November 15, 2018

November 16, 2018

·

2 min read

Drug Development

Endocyte Updates Phase III Trial Design, Sells $175 Million in Stock

Shares of Indiana-based Endocyte have slipped more than 3 percent this morning after the company announced the U.S. Food and Drug Administration accepted radiographic progression-free survival as an alternative primary endpoint in its Phase III VISION trial.

September 11, 2018

·

2 min read

·

Alex Keown

Gentilly, France, March 21, 2021: Exterior view of the Sanofi headquarters building. Sanofi is a French multinational company specializing in the health sector

Deals

Sanofi Dips Into Red-Hot Radiopharma Space With $110M Licensing Deal

Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with RadioMedix and Orano Med to develop AlphaMedix for neuroendocrine tumors.

September 12, 2024

·

1 min read

·

Annalee Armstrong

Banner. Contemporary art collage. Charity or alms. Person handing single coin to another person. Grainy fabric effect. Concept of business, financial literacy, debts, banking, salary. Ad

Deals

5 Radiopharma Biotechs to Watch for Potential Buyouts

Big Pharma can’t seem to get enough radiopharmaceutical biotechs. With Lilly, Sanofi and BMS chasing Novartis into the complex space, all eyes are on these specialty biotechs.

October 9, 2024

·

5 min read

·

Annalee Armstrong

Press Releases

Convergent Therapeutics Announces First Patient Treated in Phase II Clinical Trial with Lead Therapeutic Candidate and Corporate Updates

September 24, 2024

·

5 min read